A Phase II Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck.
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2015
At a glance
- Drugs Docetaxel (Primary) ; Erlotinib (Primary)
- Indications Head and neck cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 25 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 10 Apr 2014 Planned End Date changed from 1 Dec 2013 to 1 Feb 2016 as reported by ClinicalTrials.gov.